Ifosfamide
Ovarian Yolk Sac Tumor
Children's Oncology GroupPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Ovarian Yolk Sac Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Children's Oncology Group | Phase 3 | BB |
BLEOMYCIN Children's Oncology Group | Phase 3 | BB |
ETOPOSIDE Children's Oncology Group | Phase 3 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II Children's Oncology Group | Phase 3 | BB |
FILGRASTIM Children's Oncology Group | Phase 2 | B |
Therapeutic Allogeneic Lymphocytes National Cancer Institute (NCI) | Phase 1 | CC |
Ipilimumab National Cancer Institute (NCI) | Phase 1 | CC |
Same molecule, other indications
Ifosfamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →